Company Website
 
Contact Information:

Chris Cox
612-239-8601
ccox@ljpc.com

Virtual Web Chat:

Friday, May 21st, 12pm-4pm CT
Click here to join the meeting

Saturday, May 22nd, 8am-9am CT
Click here to join the meeting

Virtual Exhibit Hall Home

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. https://www.lajollapharmaceutical.com  

XERAVA™ (eravacycline) is the first fully synthetic fluorocycline antibacterial approved by the U.S. FDA for the treatment of complicated intra-abdominal infections.
www.Xerava.com

GIAPREZA™ (angiotensin II) is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock.
www.Giapreza.com                                                          

Additional Information

Xerava Product Overview

Xerava Tetracycline Differentiation

Xerava Prescribing Information 2006-2020

If you would like to discuss further please email Chris Cox at ccox@ljpc.com to schedule a meeting.